LGBI yields 20000000.00% · ABBV yields 3.09%● Live data
📍 LGBI pulled ahead of the other in Year 1
Combined, LGBI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LGBI + ABBV for your $10,000?
Cannabiz Mobile, Inc. operates as a mobile media and marketing company for businesses in the medical marijuana industry primarily in the United States and Canada. The company markets a subscription based, in the cloud, mobile media solution that enables care givers, dispensaries, hydroponic, and ancillary product retailers to create, deploy, and analytically measure mobile marketing campaigns using various networks and devices. It also enables businesses to create customizable personal audio and video advertisements, commercials, podcasts, and presentations that are accessible through various smart phone devices; and designs generic action pages and custom mobile Websites in which the end user has the ability to save the Mobile APP to their home screen. In addition, the company provides suppliers with mobile solutions to facilitate them in running their business through the use of the company's mobile marketing software, including mobile coupons, birthday reminders, alerts mobile business cards, mobile sites, and apps. Its software also facilitates in keeping patients informed of new medicine, as well as uses SMS text as a way to communicate for appointment reminders, refills, etc.; and provides refill reminders. The company was formerly known as Lion Gold Brazil, Inc. and changed its name to Cannabiz Mobile, Inc. in June 2014. Cannabiz Mobile, Inc. is based in Cambridge, Massachusetts.
Full LGBI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.